29 completed, 7 unknown, 4 terminated, 4 withdrawn. 10 Not applicable, 9 Phase 4, 5 Phase 1, 5 Phase 2, 3 Phase 3.
Follow Methicillin-resistant Staphylococcus Aureus: new trials by email Literature Review of Methicillin-resistant Staphylococcus Aureus trials Research Report on Methicillin-resistant Staphylococcus Aureus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PMT for MDRO Decolonization PMT - Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections | Phase 2 | Completed | University of Pennsylvania | 32 | 2024-08-19 | 2026-09-24 |
| Animal-Assisted Visitation Program Chlorhexidine Trial Chlorhexidine - Methicillin-resistant Staphylococcus Aureus, Clostridium Difficile | Phase 4 | Completed | Johns Hopkins Bloomberg School of Public Health | 45 | 2023-05-01 | 2026-10-13 |
| Povidone-Iodine for Nasal Decolonization Povidone-Iodine 10%, 0.9% NaCl Solution - Surgical Wound Infection, Preoperative Care | Phase 4 | Completed | Rutgers, The State University of New Jersey | 192 | 2022-09-06 | 2024-11-13 |
| Short and Long Term Outcomes of Doxycycline Versus Trimethoprim-Sulfamethoxazole for Skin and Soft Tissue Infections Treatment TMP-SMX, DOXY - Methicillin-resistant Staphylococcus Aureus, Skin Infection | Phase 2 | Completed | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 269 | 2018-11-26 | 2025-12-04 |
| A Study to Evaluate the Safety, PK, PD, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers N-Rephasin® SAL200, INT200-Placebo - Healthy Volunteers, Anti-Bacterial Agents | Phase 1 | Completed | Intron Biotechnology, Inc. | 33 | 2018-02-07 | 2021-11-03 |
| Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA Dalbavancin, Vancomycin, Oxacillin - Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections | Phase 3 | Completed | AbbVie | 199 | 2017-03-30 | 2024-09-19 |
| CA-MRSA Infection in China: Epidemiology, Molecular Characteristics, Treatment, and Outcome None Intervention - Community-Acquired Infections, Methicillin-resistant Staphylococcus Aureus | Unknown | Sir Run Run Shaw Hospital | 5400 | 2016-12-15 | 2017-02-27 | |
| Vancomycin Dosage Adjustment for MRSA Infections Vancomycin equation-based method, Vancomycin trough concentration method - Methicillin-Resistant Staphylococcus Aureus | Phase 4 | Unknown | Pinyo Rattanaumpawan | 114 | 2016-10-01 | 2018-01-26 |
| Trial of MRSA Polymerase Chain Reaction for Pneumonia Polymerase Chain Reaction (PCR) - Pneumonia, Methicillin-Resistant Staphylococcus Aureus | Not applicable | Completed | Northwestern University | 45 | 2016-01-01 | 2023-02-10 |
| Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence 2% mupirocin ointment, Chlorhexidine wash, Hygiene protocol - Methicillin-Resistant Staphylococcus Aureus, Recurrence | Phase 4 | Unknown | Clinical Directors Network | 278 | 2015-10-01 | 2017-07-21 |
| Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection Beta-Lactam - Methicillin-Resistant Staphylococcus Aureus | Phase 3 | Terminated | Menzies School of Health Research | 358 | 2015-08-26 | 2018-12-19 |
| Analysis of CA-MRSA Transmission: An ED Population Sampling Strategy Acute Abscess Group - Methicillin-Resistant Staphylococcus Aureus | Completed | University of Florida | 575 | 2015-08-01 | 2024-08-21 | |
| Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF) Intervention N/A. Observational study - Methicillin-Resistant Staphylococcus Aureus, Cystic Fibrosis | Completed | University of North Carolina, Chapel Hill | 48 | 2015-07-01 | 2022-01-20 | |
| Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project Vancomycin, Cystatin C dosing algorithm, Creatine clearance dosing algorithm - Methicillin-resistant Staphylococcus Aureus, Sepsis | Phase 1 | Completed | Mayo Clinic | 399 | 2014-04-01 | 2023-10-10 |
| A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers N-Rephasin® SAL200, INT200-Placebo - Healthy Volunteers, Anti-Bacterial Agents | Phase 1 | Completed | Intron Biotechnology, Inc. | 36 | 2013-08-06 | 2021-11-03 |
| Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation Vancomycin - Pneumonia, Staphylococcal, Methicillin-Resistant Staphylococcus Aureus | Phase 2 | Completed | Seoul National University Hospital | 20 | 2013-08-01 | 2019-04-23 |
| Biotherapy for MRSA Enterocolitis Fecal microbiota transplantation - Methicillin-Resistant Staphylococcus Aureus | Not applicable | Unknown | Jinling Hospital, China | 10 | 2013-07-01 | 2015-03-17 |
| Gown and Glove Use to Prevent the Spread of Infection in VA Community Living Centers Methicillin-Resistant Staphylococcus Aureus | Completed | VA Office of Research and Development | 203 | 2012-10-01 | 2017-10-05 | |
| Comparison of Bacterial Contamination Rates Between Isolation and Non-isolation Rooms Methicillin-Resistant Staphylococcus Aureus | Completed | West Virginia University | 400 | 2012-08-01 | 2015-06-02 | |
| Retapamulin for Reducing MRSA Nasal Carriage Retapamulin, Placebo - Methicillin-Resistant Staphylococcus Aureus | Phase 4 | Completed | University of California, Irvine | 53 | 2012-07-01 | 2018-04-02 |
Showing 20 of 44. Sign in to see all of them.
Cystic Fibrosis (3) · Pseudomonas Infections (2) · Soft Tissue Infections (2) · Staphylococcal Infections (2) · Staphylococcal Skin Infections (2) · Asymptomatic Infections (1) · Bacterial Infections (1) · Cellulitis (1) · Community-Acquired Infections (1) · Critical Illness (1) · Cross Infection (1) · Dermatitis, Atopic (1) · Enterobacteriaceae Infections (1) · Infections (1) · Kaposi Varicelliform Eruption (1)
Infections (18) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Bacterial Infections and Mycoses (7) · Bacterial Infections (6) · Lung Diseases (6) · Respiratory Tract Diseases (6) · Disease Attributes (5) · Gram-Positive Bacterial Infections (5) · Skin and Connective Tissue Diseases (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Genetic Diseases, Inborn (4) · Skin Diseases (4) · Skin Diseases, Infectious (4) · Digestive System Diseases (3)
Vancomycin (6) · Trimethoprim, Sulfamethoxazole Drug Combination (3) · retapamulin (3) · Chlorhexidine (2) · Doxycycline (2) · Floxacillin (2) · Inhalation (2) · Mupirocin (2) · Rifampin (2) · chlorhexidine gluconate (2) · BID protein, human (1) · Bacitracin (1) · Cefadroxil (1) · Cefazolin (1) · Cilastatin, Imipenem Drug Combination (1)
Intron Biotechnology, Inc. (2) · Tel-Aviv Sourasky Medical Center (2) · University of California, Irvine (2) · University of North Carolina, Chapel Hill (2) · AbbVie (1) · Assistance Publique - Hôpitaux de Paris (1) · Bay Pines VA Healthcare System (1) · Boston Medical Center (1) · Case Western Reserve University (1) · Clinical Directors Network (1) · Enanta Pharmaceuticals, Inc (1) · Harvard Pilgrim Health Care (1) · Horizon Health Network (1) · Jinling Hospital, China (1) · Johns Hopkins Bloomberg School of Public Health (1)
United States (27) · Israel (3) · South Korea (3) · Canada (2) · China (2) · Argentina (1) · Australia (1) · Belarus (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Colombia (1) · France (1) · Georgia (1) · Greece (1)
In Jin Jang, M.D., Ph. D. (2) · Marianne S Muhlebach, MD (2) · Alex Bekker, MD/PhD (1) · Bernard Georges, PhMD (1) · Brendan J Kelly (1) · Chris Goss, MD (1) · Christian Ramers, MD (1) · David R West, PhD (1) · Donald Leung, MD, PhD (1) · Duncan Webster, MA, MD (1) · Edward Septimus, MD (1) · Elliott C Dasenbrook, MD MHS (1) · Er-Zhen Chen, M.D. & Ph.D. (1)
PMID 11739958, PMID 12808158, PMID 14576095, PMID 15979390, PMID 18419342, PMID 18824123, PMID 23718152, PMID 25419768, PMID 27029920, PMID 27852955, PMID 28348152, PMID 28431853, PMID 28717036, PMID 28826425, PMID 30351349, PMID 30763195, PMID 30776365, PMID 32044943, PMID 32050447, PMID 35007129, PMID 35342110, PMID 36511181
2014 (1), R01CI000373 (1), R01HD097692 (1)